000			02086nam a22002657a 4500
008			171205s20172017 xxu||||| |||| 00| 0 eng d
022			_a1092-8464
040			_aOvid MEDLINE(R)
099			_a15913502
245			_aContemporary Use of Drug-eluting Stents.
251			_aCurrent Treatment Options in Cardiovascular Medicine. 7(1):35-46, 2005 May
252			_aCurr Treat Options Cardiovasc Med. 7(1):35-46, 2005 May
253			_aCurrent treatment options in cardiovascular medicine
260			_c2005
260			_fFY2005
266			_d2017-12-05
520			_aSince the era of balloon angioplasty, stents have been a revolutionary advance in the treatment of severe coronary artery disease. However, one of the major limitations is in-stent restenosis. Although brachytherapy was found to be an effective treatment, the goal remains to develop a kind of stent that will not restenose. The emergence of drug-eluting stents provided a novel solution for the reduction of restenosis. The currently approved indication for drug-eluting stents by the US Food and Drug Administration is for discrete, de novo lesions in native vessels with reference vessel diameters of 2.5 to 3.5 mm. However, in the worldwide daily practice, there have been numerous off-label uses of drug-eluting stents, and their long-term follow-up and experience in more complex lesions are accumulating. This article reviews the current off-label uses of drug-eluting stents. The majority of the supporting data are from registry and observational studies, yet many studies are limited by small sample sizes. Therefore, large, prospective, randomized, double-blind, and controlled trials are definitely warranted to further support current practice. Nevertheless, the "real world" unrestricted uses of drug-eluting stents seem to be the current trend in the interventional field.
546			_aEnglish
651			_aMedStar Heart & Vascular Instituteon
657			_aJournal Article
700			_aChu, William W
700			_aWaksman, Ron
790			_aChu WW, Waksman R
942			_cART _dArticle
999			_c2858 _d2858